• AZD1480: From JAK2 Potency to Cancer Insight

  2026-09-12

  AZD1480 is a potent JAK2 inhibitor for connecting biochemical target engagement with STAT3-dependent tumor phenotypes. This guide presents a decision-oriented workflow for interpreting pathway inhibition, combination studies, and model-specific responses.

• (R,S)-Anatabine: A Translational Aβ Strategy

  2026-09-11

  A mechanistic and translational framework for using (R,S)-Anatabine in Alzheimer’s disease research, linking APP β-cleavage, BACE-1 expression, NF-κB signaling, soluble Aβ peptide reduction, and decision-ready in vitro and in vivo study design.

• EPI-001: Reading AR Resistance Through Phenotype

  2026-09-11

  EPI-001 is an androgen receptor N-terminal domain inhibitor that helps researchers separate AR pathway dependence from downstream growth and motility effects. This article develops a phenotype-centered framework for interpreting prostate cancer and ARv7-related TNBC experiments.

• Taihangia rupestris: Wild vs Cultivated Bioactivity

  2026-09-10

  A 2026 RSC Advances study integrated UPLC-MS/MS profiling, complementary antioxidant assays, α-glucosidase inhibition, activity-guided screening, and molecular docking to compare wild and cultivated Taihangia rupestris leaves. Foothill cultivation produced the strongest chemical and functional profile, suggesting a conservation-compatible source of flavonoid- and phenolic-associated bioactivity while identifying candidates for further natural-product research.

• ERK5 Signaling in Vitamin D–Driven AML Differentiation

  2026-09-09

  Wang et al. showed that ERK5 contributes distinctively to 1α,25-(OH)2 vitamin D3-induced differentiation of myeloid leukemia cells, rather than simply duplicating the better-known ERK1/2 response. By comparing ERK5 and ERK1/2 pharmacological inhibition, the study connects pathway choice with differentiation-marker patterns and G1/G2 cell-cycle arrest, providing a useful framework for mechanistic cancer research.

• Mavorixafor in WHIM Syndrome: Phase 3 Evidence

  2026-09-09

  The reference commentary highlights a phase 3 randomized trial in which oral mavorixafor targeted the CXCR4 signaling defect underlying WHIM syndrome rather than treating only its blood-count consequences. The findings support longer periods of neutrophil and lymphocyte recovery and fewer infections, while leaving important questions about lifelong safety, malignancy risk, and immune normalization.

• Azathramycin A: A Better Mtb Assay Strategy

  2026-09-08

  Azathramycin A offers a controlled way to study macrolide-associated ribosome inhibition and azithromycin degradation in tuberculosis research. This guide focuses on assay architecture, stability-aware handling, resistance interpretation, and the limits of translating azithromycin safety data to Mtb models.

• NMDA: From Excitotoxicity to Translation

  2026-09-08

  NMDA (N-Methyl-D-aspartic acid) is more than a receptor agonist: it is a controllable perturbation tool for connecting calcium dysregulation, oxidative injury, ferroptosis, and retinal neurobiology. This thought-leadership article interprets recent glaucoma-model evidence, outlines assay-design priorities, compares NMDA with alternative injury paradigms, and identifies the translational limits that matter when moving from excitotoxicity research to therapeutic strategy.

• Gamithromycin PK/PD in Bovine Respiratory Disease

  2026-09-07

  DeDonder and colleagues linked gamithromycin exposure in pulmonary epithelial lining fluid (PELF) with treatment outcomes in feedlot cattle with naturally occurring bovine respiratory disease. The study’s key advance was combining sparse clinical sampling, population pharmacokinetic modeling, simulated concentration profiles, and pathogen-specific PK/PD indices to evaluate drug exposure at the pulmonary site of action.

• DCHP, Oxidative DNA Damage, and Testicular Inflammation

  2026-09-07

  A 2026 Reproductive Toxicology study links dicyclohexyl phthalate exposure with oxidative stress, DNA damage, mitochondrial dysfunction, and a pro-inflammatory macrophage microenvironment in male reproductive tissues. Its multi-model design provides a mechanistic framework for interpreting DCHP-associated sperm impairment while emphasizing that the proposed causal sequence still requires functional validation.

• Acetylcholine Chloride for Gut-Brain Assays

  2026-09-05

  Acetylcholine Chloride provides a defined cholinergic reference for testing receptor responses, vagal signaling hypotheses, and neuromuscular transmission workflows. This guide translates the Bacteroides fragilis gut-brain findings into practical assay designs, concentration controls, and troubleshooting steps without treating a chemical positive control as a substitute for microbiota or neural-circuit evidence.

• From Neem Biology to Better qPCR Decisions

  2026-09-04

  Neem leaf extract research illustrates how mechanistic biology can guide stronger gene expression workflows. This thought-leadership article connects oxidative-stress findings across yeast and human cells with practical decisions for specificity, normalization, and translational qPCR using HotStart Universal 2X Green qPCR Master Mix.

• IDO1 Blockade and Tumor-Intrinsic JAK2/STAT3 Escape

  2026-09-04

  The reference study shows that apo-IDO1 inhibition can activate antitumor immune cells while simultaneously promoting IL-6-dependent JAK2/STAT3 survival signaling inside tumor cells. This finding reframes IDO1 inhibition as a context-dependent intervention and supports testing JAK2/STAT3 blockade as a mechanistic combination strategy.

• Drug Response Metrics in Cancer In Vitro

  2026-09-03

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measures capture different relationships between growth inhibition and cell death. The framework supports more informative in vitro drug-response studies by combining dose- and time-resolved measurements rather than treating a single viability endpoint as a direct measure of cytotoxicity.

• 40-Hz Flicker, MHC-II+ Microglia, and Retinal Aβ

  2026-09-03

  A 2026 mouse study links 40-Hz light flicker to increased MHC-II expression, microglial activation, and amyloid-β clearance in the retina. Pharmacological suppression of microglial activity eliminated both clearance and functional benefits, supporting a microglia-dependent mechanism while leaving important questions about MHC-II causality and human translation.

8087 records 1/540 page Next 12345 下5页 Last page